Article
Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19
Registro en:
BATTAGLINI, Denise et al. Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19. Frontiers in Immunology, v. 13, Article 857573, p. 1 - 11, Apr. 2022.
1664-3224
10.3389/fimmu.2022.857573
Autor
Battaglini, Denise
Pacheco, Miquéias Lopes
Faria Neto, Hugo C. Castro
Pelosi, Paolo
Rocco, Patricia R. M.
Resumen
Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) causes a wide spectrum
of clinical manifestations, with progression to multiorgan failure in the most severe cases.
Several biomarkers can be altered in coronavirus disease 2019 (COVID-19), and they can
be associated with diagnosis, prognosis, and outcomes. The most used biomarkers in
COVID-19 include several proinflammatory cytokines, neuron-specific enolase (NSE),
lactate dehydrogenase (LDH), aspartate transaminase (AST), neutrophil count,
neutrophils-to-lymphocytes ratio, troponins, creatine kinase (MB), myoglobin, D-dimer,
brain natriuretic peptide (BNP), and its N-terminal pro-hormone (NT-proBNP). Some of
these biomarkers can be readily used to predict disease severity, hospitalization, intensive
care unit (ICU) admission, and mortality, while others, such as metabolomic and
proteomic analysis, have not yet translated to clinical practice. This narrative review
aims to identify laboratory biomarkers that have shown significant diagnostic and
prognostic value for risk stratification in COVID-19 and discuss the possible clinical
application of novel analytic strategies, like metabolomics and proteomics. Future
research should focus on identifying a limited but essential number of laboratory
biomarkers to easily predict prognosis and outcome in severe COVID-19.